NCT07001865

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia: A Cohort Study With Mediation Analysis

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 17,040 (estimated)
• Sponsor: Ningbo No. 1 Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Accepted

Summary

Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.

Conditions

• Metabolic Dysfunction-Associated Steatotic Liver Disease
• Metabolically Healthy Obesity
• Hyperuricemia

Timeline

• Start date: 2025-04-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2025-06-03
• Last updated: 2025-06-03

Locations

1 site across 1 country: China